Targeting BCR-ABL1 by PROTAC-mediated Targeted Protein Degradation - CML - Chronic myeloid leukemia
VIDEOS
PROTACs
August 16, 2019, astrazeneca
Innovation to Impact: Arvinas
May 10, 2017, Yale Innovation & Entrepreneurship
ARTICLES
Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-mediated Targeted Protein Degradation
July 16, 2019, Cancer Research
Pharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinase
September 10, 2018, Nature
Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL
November 23, 2015, NCBI
Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-mediated Targeted Protein Degradation
July 16, 2019, Cancer Research
Pharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinase
September 10, 2018, Nature
Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL
November 23, 2015, NCBI